{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:43Z","timestamp":1786991263135,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jad.2023.01.074","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:44:47Z","timestamp":1674704687000},"page":"345-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability"],"prefix":"10.1016","volume":"328","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-1976","authenticated-orcid":false,"given":"Michael","family":"Adair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3605-7223","authenticated-orcid":false,"given":"Michael Cronquist","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-9406","authenticated-orcid":false,"given":"Ioana","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-0853","authenticated-orcid":false,"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.01.074_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jad.2023.01.074_bb0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1742-7843.2011.00810.x","article-title":"Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects","volume":"110","author":"Areberg","year":"2012","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jad.2023.01.074_bb0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/JMDH.S280200","article-title":"Economic and humanistic burden associated with depression and anxiety among adults with non-communicable chronic diseases (NCCDs) in the United States","volume":"14","author":"Armbrecht","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.jad.2023.01.074_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0b013e3283530ad7","article-title":"Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder","volume":"27","author":"Baldwin","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.01.074_bb0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/da.20141","article-title":"Escitalopram in the treatment of anxiety symptoms associated with depression","volume":"24","author":"Bandelow","year":"2007","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.01.074_bb0040","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jad.2023.01.074_bb0045","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1037\/0021-843X.110.4.585","article-title":"Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample","volume":"110","author":"Brown","year":"2001","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.jad.2023.01.074_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cpr.2018.07.005","article-title":"Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis","volume":"64","author":"Buckman","year":"2018","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jad.2023.01.074_bb0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/0269881118788826","article-title":"Efficacy of vortioxetine on the physical symptoms of major depressive disorder","volume":"32","author":"Christensen","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0070","article-title":"Vortioxetine 20 mg\/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment","volume":"1\u201326","author":"Christensen","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2023.01.074_bb0075","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/02698811221090627","article-title":"Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the RECONNECT study","volume":"36","author":"Christensen","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1185\/03007995.2012.658910","article-title":"Development of a family functioning scale for major depressive disorder","volume":"28","author":"DiBenedetti","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2023.01.074_bb0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0090","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079908X291958","article-title":"The clinical relevance of changes in the Montgomery-Asberg depression rating scale using the minimum clinically important difference approach","volume":"24","author":"Duru","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2023.01.074_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0165-0327(99)00131-7","article-title":"Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression","volume":"59","author":"Fava","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.01.074_bb0105","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1017\/S0033291704002612","article-title":"Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D","volume":"34","author":"Fava","year":"2004","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.01.074_bb0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report","volume":"165","author":"Fava","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.622","article-title":"The effect of vortioxetine on overall patient functioning in patients with major depressive disorder","volume":"7","author":"Florea","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2023.01.074_bb0120","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/03007995.2017.1299701","article-title":"The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine","volume":"33","author":"Fran\u00e7ois","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2023.01.074_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/YCO.0000000000000376","article-title":"Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome","volume":"31","author":"Gaspersz","year":"2018","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","article-title":"Vortioxetine: a novel antidepressant for the treatment of major depressive disorder","volume":"14","author":"Gonda","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jad.2023.01.074_bb0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.jad.2023.01.074_bb0140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41398-021-01682-3","article-title":"Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial","volume":"11","author":"Hjorth","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0150","doi-asserted-by":"crossref","first-page":"20r13682","DOI":"10.4088\/JCP.20r13682","article-title":"Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset","volume":"82","author":"Iovieno","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder","volume":"76","author":"Jacobsen","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1017\/S2045796015000189","article-title":"Anxious and non-anxious major depressive disorder in the World Health Organization world mental health surveys","volume":"24","author":"Kessler","year":"2015","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.jad.2023.01.074_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2023.01.074_bb0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0175","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.01.074_bb0180","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796020000633","article-title":"Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries","volume":"29","author":"McGrath","year":"2020","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.jad.2023.01.074_bb0185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/NDT.S296451","article-title":"Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder","volume":"17","author":"McIntyre","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2023.01.074_bb0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/YIC.0000000000000259","article-title":"Depression with high levels of anxiety","volume":"34","author":"Montgomery","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0195","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"Montgomery","year":"2014","journal-title":"Hum. Psychopharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.jad.2023.01.074_bb0210","first-page":"9","article-title":"The importance of norepinephrine in depression","volume":"7","author":"Moret","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2023.01.074_bb0215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/da.20632","article-title":"Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials","volume":"27","author":"Nelson","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.01.074_bb0220","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pcn.12565","article-title":"Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg\/day vortioxetine in adults with major depressive disorder","volume":"72","author":"Nishimura","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.01.074_bb0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","article-title":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis","volume":"64","author":"Pae","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.01.074_bb0230","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jad.2011.03.027","article-title":"Two-year course of depressive and anxiety disorders: results from the Netherlands study of depression and anxiety (NESDA)","volume":"133","author":"Penninx","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.01.074_bb0235","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/da.23113","article-title":"Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis","volume":"38","author":"Saha","year":"2021","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.01.074_bb0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 3","key":"10.1016\/j.jad.2023.01.074_bb0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan disability scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.jad.2023.01.074_bb0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.s.7002.02","article-title":"Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse","volume":"70","author":"Simon","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.074_bb0265","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.01.074_bb0270","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1185\/03007995.2015.1135111","article-title":"Psychometric validation of the depression and family functioning scale","volume":"32","author":"Williams","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2023.01.074_bb0275","series-title":"International Statistical Classification of Diseases and Related Health Problems","year":"2019"},{"key":"10.1016\/j.jad.2023.01.074_bb0280","doi-asserted-by":"crossref","first-page":"40511","DOI":"10.1038\/srep40511","article-title":"Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:56:19Z","timestamp":1759031779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":55,"alternative-id":["S0165032723000927"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.01.074","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.01.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 H. Lundbeck A\/S. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}